抗胸腺淋巴细胞球蛋白预防肾移植后排斥反应的临床研究

Preventing cadaveric renal graft from acute rejection with anti-thymocyte globulin

本实验分别给予100例肾移植术后患者预防性应用抗胸腺淋巴细胞球蛋白(ATG)和100例肾移植术后常规应用环孢素 A(CsA)组进行了持续三个月的临床研究。结果表明:应用ATG 组肾功能恢复快(3～10天。CsA 组7～15天);急性排斥率低(ATG 组18%,CsA 为47%);肾中毒 ATG 组无,而 CsA 组15例(P<0.001),有显著差别;肝中毒及感染发生率无显著差别(P>0.05)。在应用 ATG 过程中同时测定了血清 IL-6、SIL-2R 活性,结果 ATG 组较 CsA 组明显升高。本文还对 ATG 与 CsA、IL-6、SIL-2R 关系以及 ATG 对移植后预防价值进行讨论。

A 3-month study on the comparison between 100 cadaveric kidrey transplant recipi- ents immunosuppressed with ATG and 100 control recipients with standard CsA regimen have been conducted.The results showed that the ATG group had a quicker graft function recovery (3 ～10 days to 7～15 days),lower acute rejection rate (18% to 47%) and no nephrotoxicity (0 to 15 cases,P<0.001).But the incidences of hepatoxicity and infection showed no difference be- tween the two groups.Higher serum levels of IL-6 and SIL-2R were observed in ATG group.The relationship of ATG with CsA,IL-6 and SIL-2R,and the ATG value in preventing acute rejection were discussed.